Atreca, a preclinical biotech developing immunotherapies for solid tumors, announced terms for its IPO on Monday.
The Redwood City, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. Existing stockholders have indicated an interest in purchasing up to $60 million of the IPO (48% of the deal). At the midpoint of the proposed range, Atreca would command a fully diluted market value of $484 million.
Atreca was founded in 2010 and it plans to list on the Nasdaq under the symbol BCEL. Cowen, Evercore ISI and Stifel are the joint bookrunners on the deal. It is expected to price during the week of June 17, 2019.
